Top

Published in:

01-03-2013 | Perspective

Zinc signal: a new player in osteobiology

Authors: Toshiyuki Fukada, Shintaro Hojyo, Tatsuya Furuichi

Published in: Journal of Bone and Mineral Metabolism | Issue 2/2013

Abstract

Disturbed zinc (Zn) homeostasis in mammals is mainly characterized by impaired bone generation accompanied with growth retardation. However, the underlying mechanisms that determine how Zn controls bone homeostasis remain to be defined. Zn homeostasis is tightly controlled by Zn transporter families. Recent studies have shown that Zn transporter-mediated Zn ion (Zn²⁺) behaves as a signaling factor, called Zn signal, that exerts a multiple function in cellular events, showing why Zn has a vital effect on mammalian bone growth and regeneration. This perspective put importance on the principal mechanisms of Zn participation in mammalian bone homeostasis, shifting our focus on the role of Zn from simply a nutrient to a signaling molecule that fine-tunes intracellular signaling events.

Prasad AS (1995) Zinc: an overview. Nutrition 11:93–99PubMed

Prasad AS, Halsted JA, Nadimi M (1961) Syndrome of iron deficiency anemia, hepatosplenomegaly, hypogonadism, dwarfism and geophagia. Am J Med 31:532–546PubMedCrossRef

Bergman B, Soremark R (1968) Autoradiographic studies on the distribution of zinc-65 in mice. J Nutr 94:6–12PubMed

Yamaguchi M, Gao YH (1998) Potent effect of zinc acexamate on bone components in the femoral-metaphyseal tissues of elderly female rats. Gen Pharmacol 30:423–427PubMedCrossRef

Hirano T, Murakami M, Fukada T, Nishida K, Yamasaki S et al (2008) Roles of zinc and zinc signaling in immunity: zinc as an intracellular signaling molecule. Adv Immunol 97:149–176PubMedCrossRef

Maret W (2011) Metals on the move: zinc ions in cellular regulation and in the coordination dynamics of zinc proteins. Biometals 24:411–418PubMedCrossRef

Fukada T, Yamasaki S, Nishida K, Murakami M, Hirano T (2011) Zinc homeostasis and signaling in health and diseases: zinc signaling. J Biol Inorg Chem 16:1123–1134PubMedCrossRef

Haase H, Maret W (2003) Intracellular zinc fluctuations modulate protein tyrosine phosphatase activity in insulin/insulin-like growth factor-1 signaling. Exp Cell Res 291:289–298PubMedCrossRef

Nishida K, Hasegawa A, Nakae S, Oboki K, Saito H et al (2009) Zinc transporter Znt5/Slc30a5 is required for the mast cell-mediated delayed-type allergic reaction but not the immediate-type reaction. J Exp Med 206:1351–1364PubMedCrossRef

10.

Yamashita S, Miyagi C, Fukada T, Kagara N, Che YS et al (2004) Zinc transporter LIVI controls epithelial-mesenchymal transition in zebrafish gastrula organizer. Nature (Lond) 429:298–302CrossRef

11.

Kitabayashi C, Fukada T, Kanamoto M, Ohashi W, Hojyo S et al (2010) Zinc suppresses Th17 development via inhibition of STAT3 activation. Int Immunol 22:375–386PubMedCrossRef

12.

Nilsson O, Marino R, De Luca F, Phillip M, Baron J (2005) Endocrine regulation of the growth plate. Horm Res 64:157–165PubMedCrossRef

13.

Procter AM, Phillips JA 3rd, Cooper DN (1998) The molecular genetics of growth hormone deficiency. Hum Genet 103:255–272PubMedCrossRef

14.

MacDonald RS (2000) The role of zinc in growth and cell proliferation. J Nutr 130:1500S–1508SPubMed

15.

Kronenberg HM (2003) Developmental regulation of the growth plate. Nature (Lond) 423:332–336CrossRef

16.

Rossi L, Migliaccio S, Corsi A, Marzia M, Bianco P et al (2001) Reduced growth and skeletal changes in zinc-deficient growing rats are due to impaired growth plate activity and inanition. J Nutr 131:1142–1146PubMed

17.

Michaelsson G, Ljunghall K, Danielson BG (1980) Zinc in epidermis and dermis in healthy subjects. Acta Dermato-Venereol 60:295–299

18.

Molokhia MM, Portnoy B (1969) Neutron activation analysis of trace elements in skin. 3. Zinc in normal skin. Br J Dermatol 81:759–762PubMedCrossRef

19.

Cobourne MT, Sharpe PT (2003) Tooth and jaw: molecular mechanisms of patterning in the first branchial arch. Arch Oral Biol 48:1–14PubMedCrossRef

20.

Cao X, Chen D (2005) The BMP signaling and in vivo bone formation. Gene (Amst) 357:1–8CrossRef

21.

Akhurst RJ (2004) TGF beta signaling in health and disease. Nat Genet 36:790–792PubMedCrossRef

22.

Mizuguchi T, Collod-Beroud G, Akiyama T, Abifadel M, Harada N et al (2004) Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 36:855–860PubMedCrossRef

23.

Gaither LA, Eide DJ (2001) Eukaryotic zinc transporters and their regulation. Biometals 14:251–270PubMedCrossRef

24.

Kambe T, Yamaguchi-Iwai Y, Sasaki R, Nagao M (2004) Overview of mammalian zinc transporters. Cell Mol Life Sci 61:49–68PubMedCrossRef

25.

Fukada T, Kambe T (2011) Molecular and genetic features of zinc transporters in physiology and pathogenesis. Metallomics 3:662–674PubMedCrossRef

26.

Kambe T (2011) An overview of a wide range of functions of ZnT and Zip zinc transporters in the secretory pathway. Biosci Biotechnol Biochem 75:1036–1043PubMedCrossRef

27.

Kambe T, Weaver BP, Andrews GK (2008) The genetics of essential metal homeostasis during development. Genesis 46:214–228PubMedCrossRef

28.

Huang L, Gitschier J (1997) A novel gene involved in zinc transport is deficient in the lethal milk mouse. Nat Genet 17:292–297PubMedCrossRef

29.

Chowanadisai W, Lonnerdal B, Kelleher SL (2006) Identification of a mutation in SLC30A2 (ZnT-2) in women with low milk zinc concentration that results in transient neonatal zinc deficiency. J Biol Chem 281:39699–39707PubMedCrossRef

30.

Wang X, Zhou B (2010) Dietary zinc absorption: a play of Zips and ZnTs in the gut. IUBMB Life 62:176–182PubMedCrossRef

31.

Wang K, Zhou B, Kuo YM, Zemansky J, Gitschier J (2002) A novel member of a zinc transporter family is defective in acrodermatitis enteropathica. Am J Hum Genet 71:66–73PubMedCrossRef

32.

Kury S, Dreno B, Bezieau S, Giraudet S, Kharfi M et al (2002) Identification of SLC39A4, a gene involved in acrodermatitis enteropathica. Nat Genet 31:239–240PubMedCrossRef

33.

Dufner-Beattie J, Weaver BP, Geiser J, Bilgen M, Larson M et al (2007) The mouse acrodermatitis enteropathica gene Slc39a4 (Zip4) is essential for early development and heterozygosity causes hypersensitivity to zinc deficiency. Hum Mol Genet 16:1391–1399PubMedCrossRef

34.

Wang F, Kim BE, Petris MJ, Eide DJ (2004) The mammalian Zip5 protein is a zinc transporter that localizes to the basolateral surface of polarized cells. J Biol Chem 279:51433–51441PubMedCrossRef

35.

Huang ZL, Dufner-Beattie J, Andrews GK (2006) Expression and regulation of SLC39A family zinc transporters in the developing mouse intestine. Dev Biol 295:571–579PubMedCrossRef

36.

Dufner-Beattie J, Kuo YM, Gitschier J, Andrews GK (2004) The adaptive response to dietary zinc in mice involves the differential cellular localization and zinc regulation of the zinc transporters ZIP4 and ZIP5. J Biol Chem 279:49082–49090PubMedCrossRef

37.

Wang X, Wu Y, Zhou B (2009) Dietary zinc absorption is mediated by ZnT1 in Drosophila melanogaster. FASEB J 23:2650–2661PubMedCrossRef

38.

Hojyo S, Fukada T, Shimoda S, Ohashi W, Bin BH et al (2011) The zinc transporter SLC39A14/ZIP14 controls G-protein coupled receptor-mediated signaling required for systemic growth. PLoS ONE 6:e18059PubMedCrossRef

39.

Kronenberg HM (2006) PTHrP and skeletal development. Ann N Y Acad Sci 1068:1–13PubMedCrossRef

40.

Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC (1998) Growth hormone and bone. Endocr Rev 19:55–79PubMedCrossRef

41.

Bin BH, Fukada T, Hosaka T, Yamasaki S, Ohashi W et al (2011) Biochemical characterization of human ZIP13 protein: a homo-dimerized zinc transporter involved in the spondylocheiro dysplastic Ehlers–Danlos syndrome. J Biol Chem 286:40255–40265PubMedCrossRef

42.

Fukada T, Civic N, Furuichi T, Shimoda S, Mishima K et al (2008) The zinc transporter SLC39A13/ZIP13 is required for connective tissue development; its involvement in BMP/TGF-beta signaling pathways. PLoS One 3:e3642PubMedCrossRef

43.

Fukada T, Asada Y, Mishima K, Shimoda S, Saito I (2011) Slc39a13/Zip13: a crucial zinc transporter involved in tooth development and inherited disorders. J Oral Biosci 53:1–12CrossRef

44.

Steinmann B, Royce PM (eds) (2002) Connective tissue and its heritable disorders, 2nd edn. Wiley-Liss, New York

45.

Steinmann B, Royce PM, Superti-Furga A (2002) The Ehlers–Danlos syndrome. In: Steinmann B, Royce PM (eds) Connective tissue and its heritable disorders, 2nd edn. Wiley-Liss, New York, pp 431–524CrossRef

46.

Rauch F, Glorieux FH (2004) Osteogenesis imperfecta. Lancet 363:1377–1385PubMedCrossRef

47.

Warman ML, Cormier-Daire V, Hall C, Krakow D, Lachman R et al (2011) Nosology and classification of genetic skeletal disorders: 2010 revision. Am J Med Genet A 155A:943–968PubMed

48.

Giunta C, Elcioglu NH, Albrecht B, Eich G, Chambaz C et al (2008) Spondylocheiro dysplastic form of the Ehlers–Danlos syndrome–an autosomal-recessive entity caused by mutations in the zinc transporter gene SLC39A13. Am J Hum Genet 82:1290–1305PubMedCrossRef

49.

Inoue K, Matsuda K, Itoh M, Kawaguchi H, Tomoike H et al (2002) Osteopenia and male-specific sudden cardiac death in mice lacking a zinc transporter gene, Znt5. Hum Mol Genet 11:1775–1784PubMedCrossRef

50.

Hambidge KM, Krebs NF (2007) Zinc deficiency: a special challenge. J Nutr 137:1101–1105PubMed

51.

Hambidge M (2000) Human zinc deficiency. J Nutr 130:1344S–1349SPubMed

52.

Yamasaki S, Hasegawa A, Hojyo S, Ohashi W, Fukada T et al (2012) A novel role of the L-type calcium channel alpha1D subunit as a gatekeeper for intracellular zinc signaling: zinc wave. PLOS ONE 7:e39654PubMedCrossRef

53.

Soysa NS, Alles N (2009) NF-kappaB functions in osteoclasts. Biochem Biophys Res Commun 378:1–5PubMedCrossRef

54.

Weaver BP, Dufner-Beattie J, Kambe T, Andrews GK (2007) Novel zinc-responsive post-transcriptional mechanisms reciprocally regulate expression of the mouse Slc39a4 and Slc39a5 zinc transporters (Zip4 and Zip5). Biol Chem 388:1301–1312PubMedCrossRef

Title: Zinc signal: a new player in osteobiology
Authors: Toshiyuki Fukada
Shintaro Hojyo
Tatsuya Furuichi
Publication date: 01-03-2013
Publisher: Springer Japan
Published in: Journal of Bone and Mineral Metabolism / Issue 2/2013
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-012-0409-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Racial/ethnic differences in bone mineral density among older women

A study of the link between bone turnover markers and bone mineral density with inflammation and body mass in postmenopausal women with active rheumatoid arthritis

Dissimilarity of femur aging in men and women from a Nationwide Survey in Korea (KNHANES IV)

Familial resemblance of bone turnover rate in men aged 40 and over—the MINOS study

A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients

Distribution of serum βCTX in a population-based study of postmenopausal women taking into account different anti-osteoporotic therapies (the FRODOS Cohort)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials